To Protect the Public, FDA Should Go Beyond Industry's Petition on BPA

Aimee Simpson

April 18, 2012

CPR Member Scholar Noah Sachs and I submitted comments yesterday to FDA regarding the American Chemistry Council’s (ACC) petition to the agency on BPA. In September, the ACC petitioned FDA to remove approval for the use of BPA in “infant feeding bottles and certain spill-proof cups” (Rena Steinzor and I explained at the time the story behind the seemingly counter-intuitive move).

In our comments this week, we advocate for FDA to utilize its full rulemaking authority and take broader regulatory action to protect the public against BPA.  Specifically, we propose:

  • Issuing new regulations encompassing the ACC’s Petition and Rep. Edward Markey’s March 16, 2012 Petitions concerning abandoned uses;
  • Banning a much broader range of BPA uses without reference to age limits or target consumers; and
  • Mandating labeling of BPA in all food contact materials.

As we explain in the comments, convincing scientific evidence supports these broader measures because of the demonstrated low-dose effects of BPA and other endocrine disrupting chemicals.  These low-dose effects are not properly accounted for in current risk assessments of BPA and it is the role of FDA to act on behalf of all consumers' safety.

Read More by Aimee Simpson
CPR HOMEPAGE
More on CPR's Work & Scholars.
June 10, 2021

Department of Labor's Emergency Temporary Standard Too Weak to Protect All Workers from COVID-19

June 9, 2021

CPR Scholars and Staff Back EPA's Plan to Eliminate Trump 'Benefits-Busting' Rule

June 9, 2021

What Have We Learned from Recent Disasters?

June 8, 2021

Waiting for a Reckoning: Reflections on World Oceans Day, the BP Oil Spill, and Worker Safety

June 7, 2021

The Turning Tide

June 3, 2021

Connect the Dots Podcast Explores Clean Energy Policy and Local, State, and Federal Governance

May 27, 2021

Drilled News Op-Ed: The Supreme Court’s Obscure Procedural Ruling In Baltimore’s Climate Case, Explained